Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma

The Effect of Omalizumab on Eosinophilic Inflammation of the Respiratory Tract in Patients with Allergic Asthma

“…Pelaia et al [59] showed similar results. They applied omalizumab in five asthma patients with persistent peripheral eosinophilia (mean Eo % of WBC ± SD: 15.9 ± 8.0%; Eo 1588.0 ± 956.9 cells/µl) despite long-term treatment with inhaled and systemic corticosteroids.…”

Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: a real-life experience

“…Treatment with omalizumab has been associated with a reduction or discontinuation of added on oral corticosteroid required for controlling asthma. 11,12,24 In our study, omalizumab treatment was also associated with a trend toward a reduction in the dose of inhaled corticosteroid, although this trend did not reach statistical significance. In a much larger prospective observational cohort study of moderate-to-severe allergic asthma, omalizumab therapy was associated with a reduction in doses of ICS, SABA, and leukotriene modifiers over 2 years in a "real-world" setting.…”

“…Omalizumab has been shown to reduce asthma exacerbations and hospitalization rates, as well as requirements for oral corticosteroids, in patients with allergic asthma. [6][7][8][9][10][11] The clinical benefits of omalizumab in "real-world" settings has been demonstrated consistent with the results from clinical controlled trials, providing reassurance of the improvements in outcomes in patients with uncontrolled persistent allergic asthma. [12][13][14] The long term observational studies of omalizumab have proven its efficacy in terms of sustained asthma control without rebound effect on clinical or immunological parameters.…”

An insight into pharmacological and clinical basis of anti-IgE for add-on therapy of severe asthma

“…In our experience, during add-on therapy with omalizumab, the best results can be obtained in allergic subjects with severe, uncontrolled and oral steroid-dependent asthma, characterized by the exacerbation-prone phenotype. In these patients, we have observed dramatic reductions in exacerbation rate and oral corticosteroid intake, associated with a significant improvement in lung function (FEV1 and FEV1/FVC ratio) and a relevant decrease of peripheral blood eosinophils (39). In order to predict the therapeutic response to omalizumab in allergic asthmatic patients, the EXTRA study has recently shown that elevated concentrations of biomarkers of Th2 inflammation, such as exhaled nitric oxide, peripheral blood eosinophils and serum periostin are associated, with respect to asthmatic individuals not displaying high levels of these biomarkers, with a significant greater reduction in asthma exacerbation frequency (40).…”